Evidence map›Paper›PMID 35076994›Full record

ArticleThoracic cancer2022

The impact of COVID-19 on new mesothelioma diagnoses in Italy.

Lucia Mangone, Pamela Mancuso, Isabella Bisceglia, Paolo Giorgi Rossi, Elisabetta Chellini, Corrado Negro, Lucia Benfatto, Enrica Migliore, Veronica Casotto, Carolina Mensi and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 2 countries.

Lucia MangoneReggio Emilia Cancer Registry, Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.ORCID 0000-0002-5089-5178
Pamela MancusoReggio Emilia Cancer Registry, Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Isabella BiscegliaReggio Emilia Cancer Registry, Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Paolo Giorgi RossiReggio Emilia Cancer Registry, Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Elisabetta ChelliniCOR Toscana, Unit of Occupational & Environmental Epidemiology, Institute for Cancer Research, Prevention and Clinical Network, Firenze, Italy.
Corrado NegroCOR Friuli Venezia Giulia, Azienda Ospedaliero-Universitaria "Ospedali Riuniti di Trieste" Struttura Complessa Medicina del Lavoro, Trieste, Italy.
Lucia BenfattoCOR Liguria, Epidemiologia Clinica, Istituto Nazionale per la Ricerca sul Cancro (IST-Nord), Dipartimento Terapie Oncologiche Integrate e IRCCS Azienda Ospedaliera Universitaria San Martino, Genoa, Italy.
Enrica MiglioreCOR Piemonte, Unità di Epidemiologia dei Tumori Città della salute e della scienza di Torino, Torino, Italy.
Veronica CasottoCOR Veneto, Epidemiological Department, Azienda Zero, Veneto Region, Padova, Italy.
Carolina MensiCOR Lombardia, Occupational Health Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Antonio RomanelliCOR Emilia-Romagna, Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Rosario TuminoCOR Sicilia, Cancer Registry and Histopathology Department, Provincial Health Authority (ASP 7), Ragusa, Italy.
Iolanda GrappasonniCOR Marche, School of Medicinal and Health Products Sciences, University of Camerino, Camerino, Italy.
Domenica CavoneCOR Puglia, Interdisciplinary Department of Medicine, Section Occupational Medicine B. Ramazzini, School of Medicine, University Aldo Moro Bari, Bari, Italy.
Guido MazzoleniCOR Alto-Adige, Health Trust South Tyrol, South Tyrol, Italy.
Federico TallarigoCOR Calabria, c/o UOC Anatomia Patologica PO San Giovanni di Dio, ASP, Crotone, Italy.
Alessandro MarinaccioRENAM, INAIL (Italian Workers' Compensation Authority), Occupational and Environmental Medicine, Epidemiology and Hygiene Department, Occupational and Environmental Epidemiology Unit, Rome, Italy.
ReNaM Working Group
Azienda Sanitaria Unità Locale di Reggio Emilia · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Sanitaria Universitaria Integrata di Trieste · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITIstituto Nazionale per l'Assicurazione Contro gli Infortuni sul Lavoro · ITNuovo Ospedale San Giovanni di Dio · ITOspedale Policlinico San Martino · ITPrevention Institute · USRegione del Veneto · ITRegione Siciliana · ITTechno Innovation South Tyrol (Italy) · ITUniversità di Camerino · ITUniversity of Bari Aldo Moro · IT

Funding

Regione Emilia-Romagna DGR 2045/2019 ATTO DS CUP E49E19001000002
6 · The paper itself

Abstract

backgroundThe aim of this work was to evaluate the impact of the restrictions put in place to control the COVID-19 pandemic on new diagnoses of malignant mesothelioma (MM) in Italy.

methodsTwelve of the 21 Italian malignant mesothelioma CORs (regional operating centres) participated. The study included all cases of MM with microscopic confirmation; cases without microscopic confirmation and death certificate only (DCO) were excluded. For each case, information on sex, date of birth, tumor site, morphology, and date of diagnosis was retrieved. We compared the number of incident cases in 2020 with 2019, looking at the overall picture and for four periods: pre-pandemic (January-February), first wave (March-May), low incidence (June-September), and second wave (October-December).

resultsA total of 604 cases were registered: 307 in 2019 and 297 in 2020. In the 2020 pre-pandemic period, the incidence was higher than in the same months in 2019 (+45%); there was no significant change during the first wave (+1%) or in the low-incidence period (-3%), while a decrease was observed during the second wave (-32%). However, the data were not homogeneous across the country: the increase in the pre-pandemic period concerned mostly the regions of northern (+61.5%) and central Italy (+43.5%); during the first wave, MM diagnoses increased in the northern (+38.5%) and central (+11.4%) regions but decreased in the southern regions (-52.9%). All these differences are compatible with random fluctuations.

conclusionThe COVID-19 pandemic had little or no impact on new MM diagnoses, and variations were not homogeneous throughout the country.

Indexed as

COVID-19MesotheliomaMesothelioma, MalignantHumansItalyPandemicsSARS-CoV-2COVID-19incidencemesothelioma

Identifiers

PMID35076994
PMCPMC8888152
OpenAlexW4210352236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.